↓ Skip to main content

Development of giant cell arteritis after vaccination against SARS-CoV2: A case report and literature review

Overview of attention for article published in Medicine (Wolters Kluwer), June 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

twitter
170 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Development of giant cell arteritis after vaccination against SARS-CoV2: A case report and literature review
Published in
Medicine (Wolters Kluwer), June 2023
DOI 10.1097/md.0000000000033948
Pubmed ID
Authors

Hiroki Wakabayashi, Misa Iwayanagi, Daiki Sakai, Yoshiya Sugiura, Nobuyuki Hiruta, Yasuo Matsuzawa, Kaichi Kaneko

Abstract

Giant cell arteritis (GCA) is an autoimmune vasculitis that affects large and medium-sized blood vessels. The mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has been associated with the development of immune-mediated diseases. In this article, we present a case of GCA that developed after vaccination against SARS-CoV2. A 77-year-old man developed fever, general fatigue, and headache 1 day after the third dose of vaccination against SARS-CoV2. Nodular swelling and tenderness of the bilateral temporal arteries were observed. Although right temporal artery biopsies were negative, the patient was diagnosed with GCA based on criteria established by the American College of Rheumatology for the classification of GCA. The patient received methylprednisolone 1000 mg for 3 days. This was followed by prednisolone 1 mg/kg/d, which was decreased by 10 mg every week to 30 mg. From day 16 of hospitalization, the patient received tocilizumab 162 mg/wk every other week. There was no occurrence of acute side effects. After 38 days of treatment, the condition improved and the patient was discharged from the hospital; as stated above, the dose of prednisolone was tapered to 30 mg/d. We experienced a case of GCA that occurred immediately after vaccination against SARS-CoV2 with an mRNA vaccine. Early signs of GCA include fever, fatigue, and headache, and often resemble those noted after vaccination against SARS-CoV2. The potential presence of GCA should be determined in individuals with persistent fever and headache after vaccination against SARS-CoV2.

X Demographics

X Demographics

The data shown below were collected from the profiles of 170 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Professor 1 10%
Student > Bachelor 1 10%
Other 1 10%
Student > Master 1 10%
Unknown 6 60%
Readers by discipline Count As %
Medicine and Dentistry 3 30%
Nursing and Health Professions 2 20%
Unknown 5 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 99. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2024.
All research outputs
#440,237
of 25,939,391 outputs
Outputs from Medicine (Wolters Kluwer)
#100
of 16,542 outputs
Outputs of similar age
#9,515
of 394,032 outputs
Outputs of similar age from Medicine (Wolters Kluwer)
#1
of 254 outputs
Altmetric has tracked 25,939,391 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,542 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 394,032 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 254 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.